DexCom (DXCM) Stock Forecast & Price Target

$78.00 +0.06 (+0.08%)

(As of 09:04 AM ET)

DexCom - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
6

Buy
12

Based on 18 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DXCM.

Consensus Price Target

$104.59
34.09% Upside

According to the 18 analysts' twelve-month price targets for DexCom, the average price target is $104.59. The highest price target for DXCM is $161.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 34.09% from the current price of $78.00.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

DXCM Analyst Ratings Over Time

Type	Current Forecast 11/28/23 to 11/27/24	1 Month Ago 10/29/23 to 10/28/24	3 Months Ago 8/30/23 to 8/29/24	1 Year Ago 11/28/22 to 11/28/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$104.59	$104.59	$112.25	$130.93
Forecasted Upside	34.09% Upside	45.06% Upside	61.23% Upside	16.70% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Massive shakeup in defense contracting (Ad)

There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.

You need to check out the full story right here.

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Medical Companies	S&P 500
Consensus Rating Score	2.72	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	34.19% Upside	25,264.12% Upside	6.71% Upside
News Sentiment Rating	Positive News See Recent DXCM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/25/2024	Sanford C. Bernstein 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$82.00 ➝ $86.00	+16.55%
10/25/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$120.00 ➝ $115.00	+53.54%
10/25/2024	Raymond James 4 of 5 stars		Lower Target	Strong-Buy ➝ Strong-Buy	$115.00 ➝ $99.00	+32.18%
10/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$115.00 ➝ $105.00	+39.55%
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$75.00 ➝ $85.00	+15.66%
10/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $87.00	+19.10%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
10/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$80.00 ➝ $90.00	+20.24%
8/26/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+20.74%
8/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+38.35%
8/5/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$80.00 ➝ $82.00	+13.42%
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $113.00	+67.33%
7/26/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$156.00 ➝ $120.00	+88.62%
7/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $75.00	+19.73%
7/26/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$163.00 ➝ $95.00	+49.42%
7/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $145.00	+29.87%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$130.00	+1.85%
4/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$148.00 ➝ $161.00	+15.86%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$114.00 ➝ $125.00	+16.56%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$121.00	+16.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:31 AM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 25, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

Recent analyst upgrades have increased target prices, with Sanford C. Bernstein raising their target from $82.00 to $86.00, indicating positive market sentiment and potential for stock appreciation.
The current stock price is $75.88, which is significantly lower than its fifty-two week high of $142.00, suggesting a potential buying opportunity for investors looking for value.
DexCom, Inc. has a strong market capitalization of $29.64 billion, reflecting its solid position in the medical device industry, particularly in continuous glucose monitoring systems.
The company has a healthy current ratio of 2.46, indicating that it has more than enough assets to cover its short-term liabilities, which is a positive sign for financial stability.
With a P/E ratio of 45.44, while high, it reflects investor confidence in the company's growth potential, especially in the expanding diabetes management market.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Recent downgrades from brokerages, such as StockNews.com reducing their rating from "buy" to "hold," suggest that some analysts are cautious about the stock's near-term performance.
The stock has experienced a significant decline from its fifty-two week high of $142.00, which may indicate underlying issues or market volatility that could affect future performance.
With a P/E/G ratio of 2.33, the stock may be considered overvalued relative to its growth rate, which could deter value-focused investors.
Insider ownership is relatively low at 0.30%, which may raise concerns about the alignment of management's interests with those of shareholders.
The company has a debt-to-equity ratio of 1.23, indicating that it has a higher level of debt compared to equity, which could pose risks if market conditions change.

DXCM Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $104.59, with a high forecast of $161.00 and a low forecast of $75.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
: According to analysts, DexCom's stock has a predicted upside of 34.09% based on their 12-month stock forecasts.
: DexCom has been rated by research analysts at JPMorgan Chase & Co., Leerink Partners, Oppenheimer, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and Wells Fargo & Company in the past 90 days.
: Analysts like DexCom less than other "medical" companies. The consensus rating score for DexCom is 2.72 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Massive shakeup in defense contracting (Ad)

You need to check out the full story right here.

This page (NASDAQ:DXCM) was last updated on 11/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target